Press Room

News / Nov 29, 2021

Hovione distinguished with the Order of Engineers trophy

Mrs. Diane Villax represented Hovione at the Gala of the Order of Engineers

Diane Villax receives Order of Engineers trophy | Hovione

In the picture: Herman José, presenter of the ceremony, Diane Villax, founder chairman of Hovione, António Gonçalves da Silva, President of the College of Chemical and Biological Engineering.

 
 

The Order of Engineers (OE) in Portugal celebrated its 85th anniversary and to mark the occasion held a Gala on the 27th of November. During the ceremony, OE trophies were awarded to distinguish the best projects, works, personalities or institutions of National Engineering.

Hovione was awarded for its work in the field of pharmaceutical chemistry over more than 60 years.

The award was received by Mrs. Diane Villax on behalf of Hovione. In her acceptance speech, Mrs. Diane Villax referred to Hovione's role in research and development, highlighting the important contribution given by the Team members and the PhD’s and Master programs in progress within the company.

 

Also in the Press Room

See All

Integrated approach simplifies development, reduces risk, and supports scalable manufacturing. Hovione and Industrial Design Consultancy Ltd.’s (IDC) lead single-use nasal dry powder device is now available for commercial partnerships. Hovione and IDC have completed the device design and established initial device manufacturing and supply capability, enabling pharmaceutical partners to leverage existing capsule filling infrastructure. This approach simplifies development, reduces cost and risk, and helps shorten timelines to the clinic and commercialization. “This milestone marks an important step in the evolution of our collaboration with IDC — from device innovation to a fully integrated intranasal drug delivery platform,” said Márcio Temtem, Ph.D., Vice President, Strategic Business Management, Hovione. “As the industry looks for faster, more reliable ways to bring complex therapies to patients, integration becomes critical. By bringing together nasal particle engineering science, formulation manufacturing and filling, and device technologies into a single offering, we enable a more seamless and predictable development journey, accelerating the path to market for intranasal therapies.” The nasal delivery device enables broad and targeted nasal deposition flexibility while delivering maximum usability and reliability. With a patented design and manufacturing process established, the platform is available for partnering with pharmaceutical companies on an exclusive basis as part of Hovione’s integrated offering for inhalation and nasal drug development and manufacturing. Additionally, IDC’s Managing Director, Stephen Knowles Ph.D., said the companies are now “well-advanced” with the development of a multi-use device to support an even wider range of therapies and patient needs. Read the full article at ContractPharma.com    

Press Clipping

Hovione, IDC Launch Intranasal Drug Delivery Platform

May 07, 2026